Outcomes of hepatitis C- and hepatitis B core antibody-positive grafts in orthotopic liver transplantation

Sammy Saab, Albert J. Chang, Scott Comulada, Sunil K. Geevarghese, R. Dean M. Anselmo, Francisco Durazo, Steven Han, Douglas G. Farmer, Hasan Yersiz, Leonard I. Goldstein, R. Mark Ghobrial, Ronald W. Busuttil

Research output: Contribution to journalArticle

64 Scopus citations

Abstract

The use of hepatitis B core antibody (HBcAb)- and hepatitis C virus antibody (HCV+) liver grafts for transplantation in selected populations has not affected patient and graft survival. We reexamined the clinical outcomes of using these HBcAb+ and HCV+ grafts at our institution, in addition to studying recipients of combined HBcAb+/ HCV+ grafts. We identified 377 patients who underwent transplantation for either hepatitis B and/or hepatitis C, or received both HBcAb+ and HCV+ grafts. Patient and graft survival at 5 years posttransplantation was 73% and 71%, respectively, in the HBcAb+ grafts compared with 81% and 75% in the HBcAb- grafts (P =.65; P =.94). For HCV+ grafts, patient and graft survival at 5 years posttransplantation was 89% and 73%, respectively, compared with 69% and 59% in the HCV- grafts; (P =.22; P =.77). The 5-year patient and graft survival rate in those who received combined HBcAb+/HCV+ grafts was 74% and 69%, respectively, and there was no statistical difference compared with the HBcAb+ and HCV+ grafts (P =.76; P =.90). The 5-year patient and graft survival rate in patients who received dual HBV prophylaxis with hepatitis B immunoglobulin (HBIg) and lamivudine was 88% and 84%, respectively, which was significantly higher than for patients who received single prophylaxis or no prophylaxis (P <.01; P =.02). Our study supports previous observations that patient and graft survival is not affected with the use of HBcAb+ and HCV+ grafts, and that dual prophylaxis with HBIg and lamivudine offers substantial survival benefits. Furthermore, the use of combined HBcAb+/HCV+ grafts did not impact patient or graft survival. This provides a potential new pool of donor livers that can be used for transplantation in select patients.

Original languageEnglish (US)
Pages (from-to)1053-1061
Number of pages9
JournalLiver Transplantation
Volume9
Issue number10
DOIs
StatePublished - Oct 2003

ASJC Scopus subject areas

  • Surgery
  • Hepatology
  • Transplantation

Fingerprint Dive into the research topics of 'Outcomes of hepatitis C- and hepatitis B core antibody-positive grafts in orthotopic liver transplantation'. Together they form a unique fingerprint.

Cite this